We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Lamotrigine for Ketamine Dependence Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02556060
Recruitment Status : Completed
First Posted : September 22, 2015
Last Update Posted : February 1, 2018
Chang Gung Memorial Hospital
Information provided by (Responsible Party):
Lin, Shih-Ku, Taipei City Hospital

Tracking Information
First Submitted Date  ICMJE September 8, 2015
First Posted Date  ICMJE September 22, 2015
Last Update Posted Date February 1, 2018
Study Start Date  ICMJE September 2015
Actual Primary Completion Date May 1, 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 20, 2015)
Urine drug screen [ Time Frame: 12 weeks ]
Negative result of urinary drug toxicology screen of ketamine
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 20, 2015)
  • subjective visual analogue scales of craving [ Time Frame: 12 weeks ]
    Scores of subjective visual analogue scales of craving rated by patient
  • Retention rate [ Time Frame: 12 weeks ]
    Rate of patients stay in this trial
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Lamotrigine for Ketamine Dependence Trial
Official Title  ICMJE Lamotrigine for Ketamine Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial
Brief Summary The purpose of this study is to investigate the efficacy of lamotrigine in the treatment of ketamine dependence in a double-blind, placebo controlled design.
Detailed Description


Ketamine is an anesthetic derivative of phencyclidine (PCP; 'Angel dust') with dissociative, analgesic and psychedelic properties. Recreational use of ketamine was first documented on the west coast of the United States in the early 1970s. Ketamine is frequently described as a "unique drug" because it shows hypnotic (sleep producing), analgesic (pain relieving) and amnesic (short-term memory loss) effects; no other drug used in clinical practice combines these three important features at the same time. Ketamine produces an anaesthetic state, which has been termed "dissociative anaesthesia", characterized by analgesia and changes in vigilance and perception, but it is not a sedative or hypnotic. It appears that ketamine selectively interrupts the thalamocortical system. Ketamine has some anxiolytic- and antidepressant-like properties in sub-anesthetic doses.

Mechanism of ketamine addiction

The existence of binding sites for PCP and ketamine were first identified in 1979. Earlier reports indicate that ketamine essentially blocks the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. The antagonism of NMDA receptor is responsible for its specific properties including psychedelic, anesthetic, analgesic, anxiolytic, antidepressant, hypnotic effects and cognitive impairment. In fact, ketamine also binds to non-NMDA glutamate receptors and involves glutamate-independent mechanisms associated with nicotinic and muscarinic cholinergic, monoaminergic and opioid receptors.

Currently there is no specific pharmacological treatment model for ketamine dependence. Continuous urine screen plus medications for psychiatric symptoms treatment revealed fair results.

Study drug: Lamotrigine

Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. Besides it's sodium channels blocking effect as an antiepileptic drugs, lamotrigine also inhibits the release of glutamate through modulation of high voltage-activated calcium currents and sodium channels.


Patient Patients with ketamine use disorder seeking treatment at Taipei City Hospital and Psychiatric Center will be invited to participate this clinical trial. Treatment and assessment Schedule After informed consent signature with explanations about the procedure of this study, the initiation includes collecting drug use history and medical history, conducting a physical examination, and performing clinical laboratory tests.

The study duration will last for 12 weeks and patients will be monitored at week 0, week 1, week 2, week 4, week 8, and week 12 for 6 times. Urinary toxicology and visual analogue scales will be checked at each visit and laboratory chemistry at each visit.


The study subjects will be randomly assigned by computer-generated numbers either to the lamotrigine or placebo group in a 1:1 ratio.

Dosage of trial medication

Trial medication and placebo will be sponsored by Lotus pharmaceutical, Taiwan. It is an extended release tablet form of lamotrigine or identical placebo. The preparation of double procedure will be handled by the Department of Pharmacy of Taipei City Hospital.

Once a subject enters the treatment phase (after randomization) the dosage of study medication will be 25 mg/before bed (or one half placebo tablet at night) for 7 days. On day 8 (visit 2 or the beginning of week 2), the dosage will be increased, as tolerated, to 50 mg/day for another week. After then, the dosage will be increased to 100 mg/day (QD and HS) for 2 weeks. After 4 weeks, the dosage may be kept or increased, as judged by investigator, at the range of 100mg to 200mg /day to the end of 12 weeks. The dosage may be decreased at any time because of side effects, but not less than 100 mg. If the patient prefers, he or she may take all of his or her daily dose of medication in the morning or evening.

The enroll period will be 2 years and total study duration will be 3 years.

Concomitant and prohibited medications

During study period, patients can take their original medications for systemic disorder. Due to patients with drug abuse usually have depressed mood, emotional disturbance or sleep problems during withdrawal period, benzodiazepines, or short acting novel hypnotics such as zolpidem or zaleplon can be used for ethical consideration. For those patient treated with antipsychotics due to drug-induced psychosis, the patients can be enrolled only when the psychotic symptoms remitted and lowest dose of antipsychotic can be used during the trial period. The prohibited medications include medications which have drug-drug interaction such as carbamazepine, phenytoin barbiturates, rifampicin, chlordiazepoxide and oral hypoglycaemics.

Primary endpoint

The primary endpoint will be the results from urinary drug screen of ketamine, and other substances including amphetamine, methylenedioxymethamphetamine, morphine and cannabis, which will be carried out at the baseline and during each visit of the study period.

Secondary endpoint

Subjective visual analogue scales of craving by patient and subjective clinical global impression of severity will be the second endpoint. The Brief Addiction Severity Index of ketamine use will also be analyzed.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Addiction
Intervention  ICMJE
  • Drug: Lamotrigine
    Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
    Other Name: Lamofree ER
  • Drug: Placebo
    Same dosing schedule as study drug
    Other Name: Identical to Lamofree ER
Study Arms  ICMJE
  • Experimental: lamotrigine
    lamotrigine extended release up to 200 mg/day,
    • Drug: Lamotrigine
    • Drug: Placebo
  • Placebo Comparator: Placebo
    Identical Placebo
    • Drug: Lamotrigine
    • Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 31, 2018)
Original Estimated Enrollment  ICMJE
 (submitted: September 20, 2015)
Actual Study Completion Date  ICMJE May 1, 2017
Actual Primary Completion Date May 1, 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Current users of ketamine, including having a ketamine-positive urine
  2. Meeting DSM-5 criteria for ketamine use disorder
  3. Age between 18 to 65 years old
  4. Women of childbearing age must have a negative pregnancy test to enroll in this study, agree to monthly pregnancy testing, and agree to use appropriate forms of birth control for the duration of the study.

Exclusion Criteria:

  1. Significant medical conditions such as abnormal liver function or renal function confirmed by laboratory tests
  2. Hypertension
  3. A current cardiac condition or high risk of cardiovascular disease
  4. Seizure disorders
  5. Any another significant underlying medical condition which would contraindicate lamotrigine treatment
  6. Meeting DSM-IV psychiatric classifications for schizophrenia, bipolar disorder, or other psychotic disorders
  7. Meeting DSM-IV psychiatric classifications for substance use disorder other than ketamine within three month except tobacco or caffeine.
  8. Exhibiting current suicidality or homicidality
  9. Pregnant women, lactating women or women who are planning to be pregnant.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Taiwan
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT02556060
Other Study ID Numbers  ICMJE TCHIRB-102309
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Lin, Shih-Ku, Taipei City Hospital
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Taipei City Hospital
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Chang Gung Memorial Hospital
Investigators  ICMJE
Principal Investigator: Shih-Ku Lin, MD Taipei City Hospital
PRS Account Taipei City Hospital
Verification Date January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP